• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

New indication approved for asthma drug

Article

Merck received FDA approval for a new indication for montelukast 10 mg (Singulair). The medication can now be prescribed for exercise-induced bronchoconstriction (EIB) in patients 15 years and older [more].

Merck received FDA approval for a new indication for montelukast 10 mg (Singulair). The medication can now be prescribed for exercise-induced bronchoconstriction (EIB) in patients 15 years and older [more].

According to the manufacturer, a single dose prevented EIB when taken two hours before exercise. Some patients benefited from the drug at 8.5 and 24 hours after administration, however some did not. Symptoms include shortness of breath, cough, wheeze, and chest tightness brought on by exercise. EIB affects a broad spectrum of patients with asthma.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.